High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification?

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1647-1654

  Sandor Kiss, Lajos ^a   Papp, Maria ^b   Dorottya Lovasz, Barbara ^a   Vegh, Zsuzsanna ^a   Anna Golovics, Petra ^a   Janka, Eszter ^b   Varga, Eva ^b   Szathmari, Miklos ^a   Lakatos, Peter Laszlo ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

CD; clinical activity; flare up; hs CRP; prediction; risk

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN;

ACCURACY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELAPSE; SMOKING;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REFERRAL AND CONSULTATION;

EID: 84865003772     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21933     Document Type: Article

References (31)

1. Lakatos PL, Kiss LS,. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol. 2010; 16: 2591-2599.
2. Vermiere S, Van Assche G, Rutgeerts P,. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431.
3. Darlington GJ, Wilson DR, Lachman LB,. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 1986; 103: 787-793.
4. Schuetz P, Christ-Crain M, Müller B,. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care. 2007; 13: 578-585.
5. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982; 12: 351-359.
6. Tromm A, Tromm CD, Hüppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol. 1992; 27: 774-778.
7. Zilberman L, Maharshak N, Arbel Y, et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion. 2006; 73: 205-209.
8. Lakatos PL, Kiss LS, Palatka K, et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis. 2011; 17: 767-777.
9. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis. 2005; 11: 707-712.
10. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006; 12: 551-557.
11. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57; 1518-1523.
12. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988; 10: 401-405.
13. Schreiber S, Khaliq-Kareemi M, Lawrance JC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Eng J Med. 2010; 362: 1383-1395.
16. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24 (Suppl 170): 2-6.
17. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
18. Vermiere S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's Disease Activity and Harvey-Bradshaw Indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010; 8: 357-363.
19. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010; 4: 7-27.
20. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (Suppl i): i1-i15.
21. Best WR,. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006; 12: 304-310.
22. Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 882-887.
23. Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis. 2007; 39: 1006-1010.
24. Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006; 41: 306-311.
25. Jürgens M, Mahachie John JM, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9: 421-427.
26. Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalization of CRP are the strongest predictors of efficacy, mucosal healing, and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011; 34: 911-922.
27. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1599-1604.
28. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008; 6: 1218-1224.
29. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
30. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22.
31. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368.